Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTG-100 in Celiac Disease
NCT04524221Phase 1Completed
- Sponsor
- Nielsen Fernandez-Becker
- Start
- Feb 2021
- Primary completion
- Apr 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in celiac disease comparing PTG-100 with Placebo (2 arms). Primary endpoint: Percentage change in villous height-to crypt ratio at 42 days. Started Feb 2021; status: completed.
02
Drugs
PTG-100
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT04524221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524221.